Xiang X - Search Results

1

Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma.

Liu S, Sui J, Luo B, Zhang J, Xiang X, Yang T, Luo Y, Liu J. Liu S, et al. Among authors: xiang x. J Med Chem. 2024 Jul 11;67(13):10622-10642. doi: 10.1021/acs.jmedchem.4c00080. Epub 2024 Jun 21. J Med Chem. 2024. PMID: 38905539

2

Targeting mitochondrial proteases for therapy of acute myeloid leukaemia.

Xiang X, Bao R, Wu Y, Luo Y. Xiang X, et al. Br J Pharmacol. 2022 Jul;179(13):3268-3282. doi: 10.1111/bph.15844. Epub 2022 Apr 15. Br J Pharmacol. 2022. PMID: 35352341 Free article. Review.

3

Epigenetic changes in Mycobacterium tuberculosis and its host provide potential targets or biomarkers for drug discovery and clinical diagnosis.

Sui J, Qiao W, Xiang X, Luo Y. Sui J, et al. Among authors: xiang x. Pharmacol Res. 2022 May;179:106195. doi: 10.1016/j.phrs.2022.106195. Epub 2022 Mar 29. Pharmacol Res. 2022. PMID: 35364247

4

Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response.

Zhang J, Qiu Z, Liu S, Huang J, Luo B, Sui J, Dai Z, Xiang X, Yang T, Luo Y. Zhang J, et al. Among authors: xiang x. J Med Chem. 2024 Feb 22;67(4):2812-2836. doi: 10.1021/acs.jmedchem.3c01950. Epub 2024 Feb 8. J Med Chem. 2024. PMID: 38329974

5

Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity.

Xiang X, Dai Z, Luo B, Zhao N, Liu S, Sui J, Huang J, Zhou Y, Gu J, Zhang J, Yang T, Bao R, Luo Y. Xiang X, et al. J Med Chem. 2024 Apr 25;67(8):6769-6792. doi: 10.1021/acs.jmedchem.4c00338. Epub 2024 Apr 15. J Med Chem. 2024. PMID: 38620134

6

Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.

Li H, Xiang X, Ding H, Yu J, Xu J, Yuan Y, Wu Y. Li H, et al. Among authors: xiang x. Br J Haematol. 2022 Dec;199(5):768-771. doi: 10.1111/bjh.18476. Epub 2022 Sep 28. Br J Haematol. 2022. PMID: 36169236 Free PMC article. No abstract available.

7

[The Influence of Glutamic Pyruvate Transaminase 2 to Biological Characteristics of Acute Myeloid Leukemia Cell HL-60].

Xiang XR, Li Q, Yu Y, Wu Y. Xiang XR, et al. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Apr;29(2):408-415. doi: 10.19746/j.cnki.issn.1009-2137.2021.02.016. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021. PMID: 33812407 Chinese.

8

Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.

Song H, Wu J, Tang Y, Dai Y, Xiang X, Li Y, Wu L, Wu J, Liang Y, Xing Y, Yan N, Li Y, Wang Z, Xiao S, Li J, Zheng D, Chen X, Fang H, Ye C, Ma Y, Wu Y, Wu W, Li J, Zhang S, Lu M. Song H, et al. Among authors: xiang x. Sci Transl Med. 2023 Apr 5;15(690):eabn9155. doi: 10.1126/scitranslmed.abn9155. Epub 2023 Apr 5. Sci Transl Med. 2023. PMID: 37018419

9

Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.

Zhao L, Yang J, Chen M, Xiang X, Ma H, Niu T, Gong Y, Chen X, Liu J, Wu Y. Zhao L, et al. Among authors: xiang x. Ann Hematol. 2024 Apr;103(4):1197-1209. doi: 10.1007/s00277-024-05646-7. Epub 2024 Feb 8. Ann Hematol. 2024. PMID: 38329487

10

Armor sign on PET-CT in a young male with non-Hodgkin's lymphoma.

Yang CL, Xiang XR, Wu Y. Yang CL, et al. Int J Hematol. 2022 Jan;115(1):5-6. doi: 10.1007/s12185-021-03258-9. Epub 2021 Nov 11. Int J Hematol. 2022. PMID: 34766238 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,480 results

Search Page

Filters